SHP.L - Shire plc

LSE - LSE Delayed price. Currency in GBp
3,566.50
-112.00 (-3.04%)
As of 1:12PM GMT. Market open.
Stock chart is not supported by your current browser
Previous close3,678.50
Open3,642.00
Bid3,565.50 x 51000
Ask3,567.00 x 53800
Day's range35.67 - 3,646.00
52-week range35.67 - 5,067.00
Volume1,010,524
Avg. volume2,704,773
Market cap32B
Beta1.80
PE ratio (TTM)47.87
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.26 (0.51%)
Ex-dividend date2016-09-08
1y target estN/A
  • Reuters6 days ago

    Tesco, Vodafone keep FTSE afloat

    By Danilo Masoni and Kit Rees MILAN (Reuters) - Britain's top stock index steadied on Tuesday as Tesco (TSCO.L) rallied after it won approval for a takeover and Vodafone (VOD.L) reported strong results, ...

  • Shire Gets Positive CHMP Opinion for Hemophilia A Drug
    Zacks6 days ago

    Shire Gets Positive CHMP Opinion for Hemophilia A Drug

    Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

  • Poor earnings updates keep European shares at seven-week low
    Reuters7 days ago

    Poor earnings updates keep European shares at seven-week low

    The pan-European STOXX 600 (.STOXX) was 0.7 percent lower at its close, with almost every sector ending in negative territory. France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. Exane BNP Paribas affirmed its underperform rating on EDF.

  • Reuters - UK Focus7 days ago

    Poor earnings updates keep European shares at 7-week low

    France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. This was due to lower than expected power consumption, lower availability of some of its nuclear reactors in early 2018 and a drop in capacity compensation in Britain.

  • Why Motif Bio plc is a growth bargain I’d buy and hold for 25 years
    Fool.co.uk8 days ago

    Why Motif Bio plc is a growth bargain I’d buy and hold for 25 years

    Motif Bio PLC (LON: MTFB) has a bright outlook but growth will take time.

  • The Only 3 Big Pharma Companies Growing Market Share
    Motley Fool13 days ago

    The Only 3 Big Pharma Companies Growing Market Share

    Most big pharma companies will actually lose market share over the next few years. These three will gain market share -- but in very different ways.

  • FTSE surges after BoE's 'dovish' hike hits sterling
    Reuters18 days ago

    FTSE surges after BoE's 'dovish' hike hits sterling

    By Danilo Masoni and Helen Reid MILAN/LONDON (Reuters) - Britain's top share index posted its biggest rise in over three months on Thursday after the Bank of England tempered investors' expectations on ...

  • Reuters - UK Focus18 days ago

    BUZZ-Xenetic Biosciences Inc: Soars on deal with Shire's unit

    ** Drug developer's shares up as much as 67.19 pct to $3.7 - stock top pct gainer on Nasdaq, after it says entered agreement to license rights of certain patents related to its drug development platform ...

  • Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
    Zacks21 days ago

    Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

    Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

  • MarketWatch21 days ago

    Fund manager, analysts make the case for this ‘loathed’ pharma stock

    Irish pharmaceutical giant Shire has seen its shares slump this year, turning in one of the worst performances among United Kingdom-listed blue chips. The bear case may have some cracks in it, however....

  • Reuters24 days ago

    Shire to make genetic disease drug itself to secure supply

    Shire (SHP.L) will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit. "We delivered strong growth this quarter with product sales up 7 percent to $3.5 billion(£2.67 billion) despite a Cinryze supply shortage and a Lialda generic entry," Shire Chief Executive Flemming Ornskov said in a statement. Ornskov said Shire's immunology drugs to treat diseases like Guillain-Barre syndrome performed strongly in the quarter and growth in the franchise it acquired by buying Baxalta last year rose from a historical rate of 6-8 to 21 percent year to date.

  • Reuters - UK Focus24 days ago

    Shire to make genetic disease drug itself to secure supply

    LONDON, Oct (Shenzhen: 000069.SZ - news) 27 (Reuters) - Shire (Xetra: S7E.DE - news) will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit. "We delivered strong growth this quarter with product sales up 7 percent to $3.5 billion despite a Cinryze supply shortage and a Lialda generic entry," Shire Chief Executive Flemming Ornskov said in a statement. Ornskov said Shire's immunology drugs to treat diseases like Guillain-Barre syndrome performed strongly in the quarter and growth in the franchise it acquired by buying Baxalta (Xetra: 9BX.DE - news) last year rose from a historical rate of 6-8 to 21 percent year to date.

  • Fool.co.uk24 days ago

    One FTSE 100 turnaround stock I’d buy and one I’d sell

    Roland Head looks takes a bold view on two battered FTSE 100 (INDEXFTSE:UKX) stocks.

  • Associated Press24 days ago

    Shire beats 3Q profit forecasts

    On a per-share basis, the Dublin-based company said it had net income of $1.81. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to $3.81 per share. The results ...

  • Fool.co.uk27 days ago

    2 beaten-up FTSE 100 stocks: is now the time to buy?

    Edward Sheldon looks at two FTSE 100 (INDEXFTSE:UKX) stocks that are way off their highs. Are these stocks now bargains?

  • Shire's New Formulation of Oncaspar Gets CHMP Recommendation
    Zackslast month

    Shire's New Formulation of Oncaspar Gets CHMP Recommendation

    Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.

  • Activist fund seeks break-up of £35bn pharma group Shire
    Sky Newslast month

    Activist fund seeks break-up of £35bn pharma group Shire

    A US hedge fund is demanding a string of divestments at the FTSE-100 biotech group Shire (Xetra: S7E.DE - news) , underlining growing interest among activist investors in large European companies. Sky News has learnt that Sachem Head Capital Management is urging the board of Shire, which specialises in treatments for rare diseases and neuroscience products, to explore a sale or spin-off of several of its assets. The move, which has been raised during discussions between the hedge fund and Shire directors in recent months, comes after Sachem Head disclosed during the summer that it had acquired a small stake in the pharmaceuticals group.

  • The Wall Street Journal2 months ago

    Shire Alleges Allergan Blocked Drug From Medicare Contracts

    Shire filed an antitrust suit against Allergan, alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug.

  • Reuters2 months ago

    Shire sues Allergan in U.S. over dry eye drug

    In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra. "Quite simply, Allergan has and will continue to use bundled discounts, exclusive dealing, coercion and interference to unlawfully 'block' Shire from competing with it, and to maintain its monopoly in the Part D market at all costs," Shire said, referring to the Medicare drug plans.

  • Reuters - UK Focus2 months ago

    Shire sues Allergan in U.S. over dry eye drug

    Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - Allergan Plc (Frankfurt: A1W5NE - news) was sued on Monday by Shire Plc (Xetra: S7E.DE - news) for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease. In a complaint filed with the federal court in Newark, New (KOSDAQ: 160550.KQ - news) Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra. "Quite simply, Allergan has and will continue to use bundled discounts, exclusive dealing, coercion and interference to unlawfully 'block' Shire from competing with it, and to maintain its monopoly in the Part D market at all costs," Shire said, referring to the Medicare drug plans.

  • Reuters - UK Focus2 months ago

    Shire says trial shows new HAE drug significantly reduces attacks

    London-listed drugmaker Shire (Hamburg: 3979575.HM - news) said on Monday it had successfully tested a new medicine that prevents attacks in patients with hereditary angioedema (HAE), a rare genetic disease that causes swelling of extremities, the gastrointestinal tract and upper airways. "We are very pleased with the strong results of this study, which demonstrated efficacy with a low-volume dosing regimen, and what it potentially could mean for the global HAE community, if approved," said Shire (Xetra: S7E.DE - news) 's head of research and development, Howard Mayer.

  • Reuters - UK Focus3 months ago

    Shire defends record as UBS cuts price target on staff satisfaction reviews

    Shire (Xetra: S7E.DE - news) is weathering a period a major change well, the company said on Tuesday, as analysts at UBS (LSE: 0QNR.L - news) cut their price target on the stock in response to signs of falling staff satisfaction at the drugmaker. A trawl of 20,000 employee reviews from careers website Glassdoor showed a major decline in staff satisfaction at Shire (Hamburg: 3979575.HM - news) in 2017, with the company coming 24th out of 26 biopharmaceutical companies on "overall satisfaction", UBS said. Shire, which recently lost its chief financial officer and head of research, faces testing times after buying United (Shenzhen: 000925.SZ - news) States-based Baxalta (Xetra: 9BX.DE - news) in its biggest ever deal, leading to inevitable upheaval and challenges.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes